2002
DOI: 10.1067/mhj.2002.120292
|View full text |Cite
|
Sign up to set email alerts
|

The renal dopaminergic system, neurohumoral activation, and sodium handling in heart failure

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
6
0

Year Published

2004
2004
2014
2014

Publication Types

Select...
4
3

Relationship

1
6

Authors

Journals

citations
Cited by 14 publications
(6 citation statements)
references
References 22 publications
0
6
0
Order By: Relevance
“…In humans, all of the DA in urine is derived from uptake of circulating DOPA [86]. DA exiting the proximal tubular cells acts on the same or nearby cells to augment sodium excretion [87]. Most of the DA synthesized in the body is formed in non-neuronal cells in splanchnic organs, not the brain or sympathetic nervous system [88].…”
Section: Catecholamine Reactivity To Mental Stressmentioning
confidence: 99%
“…In humans, all of the DA in urine is derived from uptake of circulating DOPA [86]. DA exiting the proximal tubular cells acts on the same or nearby cells to augment sodium excretion [87]. Most of the DA synthesized in the body is formed in non-neuronal cells in splanchnic organs, not the brain or sympathetic nervous system [88].…”
Section: Catecholamine Reactivity To Mental Stressmentioning
confidence: 99%
“…The renal DOPA-DA system is upregulated in heart failure (98), possibly as part of a compensatory process. Renalase, a relatively recently described amine oxidase, metabolizes urinary catecholamines, and it has been proposed that renalase in luminal fluid might alter DA metabolism and proximal tubular sodium transport (62).…”
Section: Applications Of Concepts Of Scientific Integrative Medicine mentioning
confidence: 99%
“…The increases in sympathetic tone seen in association with CHF are associated with poorer outcome, morbidity and mortality. These could be mediated by peripheral vasoconstriction, enhanced sodium retention, attenuated cardiovascular reflexes and increased susceptibility to arrhythmia and/or sudden death [15][16][17][18]. Accordingly we have used HRV studies to assess the impact of Atorvastatin on autonomic tone in SHF Methods 23 consecutive patients from our systolic heart failure clinic (19 men and 3 women; mean age 67 ± 10 years) with stable systolic left ventricular impairment (documented ejection fraction (EF) <45% on radionuclide ventriculography and/or echocardiography) and who were not currently on statin therapy were randomised single (patient) blind to receive either Atorvastatin (40 mg/day) or to continue with their usual regimen of SHF treatment with a placebo.…”
Section: Introductionmentioning
confidence: 98%